NIP
IMMU

Nicholas Investment Partners’s Immunomedics Inc IMMU Stock Holding History

Nicholas Investment Partners’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-245,698
Closed -$20.9M – 197
2020
Q3 		$20.9M Buy
245,698
+146,549
+148% +$7.41M 2.26% 3
2020
Q2 		$3.51M Sell
99,149
-146,673
-60% -$4.29M 0.71% 47
2020
Q1 		$3.31M Buy
245,822
+12,177
+5% +$205K 0.65% 63
2019
Q4 		$4.94M Sell
233,645
-121,171
-34% -$2.14M 0.51% 55
2019
Q3 		$4.71M Buy
354,816
+39,904
+13% +$587K 0.4% 94
2019
Q2 		$4.37M Buy
314,912
+66,881
+27% +$1.01M 0.4% 90
2019
Q1 		$4.76M Sell
248,031
-55,759
-18% -$899K 0.42% 74
2018
Q4 		$4.33M Buy
303,790
+27,156
+10% +$539K 0.47% 69
2018
Q3 		$5.76M Sell
276,634
-56,137
-17% -$1.33M 0.46% 69
2018
Q2 		$7.88M Buy
332,771
+29,470
+10% +$592K 0.55% 41
2018
Q1 		$4.43M Sell
303,301
-11,074
-4% -$181K 0.32% 104
2017
Q4 		$5.08M Sell
314,375
-19,904
-6% -$235K 0.34% 84
2017
Q3 		$4.67M Buy
+334,279
New +$3.33M 0.32% 94

Nicholas Investment Partners's IMMU Position: Q4 2020 in Review

Nicholas Investment Partners sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 245,698 shares — an estimated $20.9M sold.

Nicholas Investment Partners first reported a position in IMMU in Q3 2017 and held it in 13 quarters. The position peaked at $20.9M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • Nicholas Investment Partners reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • Nicholas Investment Partners sold 245,698 Immunomedics Inc shares in Q4 2020, an estimated $20.9M.
  • Nicholas Investment Partners first reported a position in Immunomedics Inc in Q3 2017 and held it in 13 quarters.
  • Nicholas Investment Partners's Immunomedics Inc position peaked at $20.9M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Nicholas Investment Partners's 13F filing for Q4 2020, filed 11 Feb 2021.